IRT Platform (e.g., COVID-19)
COVID-19 Prevention
Research/Pre-clinicalActive
Key Facts
About Biological Mimetics
Biological Mimetics is a private, pre-revenue biotechnology company with a 25+ year history, specializing in novel vaccine and diagnostic platforms. Its lead technologies include IRT (Immune Refocusing Technology) for creating more broadly protective vaccines and MDP (Manganese-Decapeptide-Phosphate) for pathogen inactivation, with an advanced program in ultraIPV (inactivated polio vaccine). The company also collaborates on FAST, a portable CRISPR-based diagnostic tool designed for low-resource settings. BMI operates through partnerships to advance its platforms toward the market.
View full company profileTherapeutic Areas
Other COVID-19 Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Intranasal COVID Vaccine | Virpax Pharmaceuticals | Research |
| COVID-19 Vaccine Trials | DM Clinical Research | Not Specified |
| SARS-CoV-2 Vaccine | Epygen Biotech | Not Disclosed |
| COVAXIN | Bharat Biotech | Commercial |
| iNCOVACC | Bharat Biotech | Commercial |
| Replicon RNA COVID-19 Vaccine | BIKEN Group | Preclinical/Development |
| Convidecia Air® (XBB.1.5 Variant) | CanSino Biologics | Approved |
| COVID-19 Vaccine | Recbio Technology | Not specified |
| COMIRNATY® (BNT162b2) | Fosun Pharma | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| Recombinant Protein COVID-19 Vaccine | Sinopharm | Approved |
| COVID-19 mRNA Vaccine (SYS6006) | CSPC Innovation Pharmaceutical | Marketed |